摘要
目的制定云南省降尿酸药品的临床综合评价与遴选标准体系,为云南省医疗机构降尿酸药品的合理使用提供参考依据。方法依据权威指南及药品说明书等相关资料,运用德尔菲专家咨询法,建立云南省降尿酸药品临床综合评价与遴选标准,并运用此评分标准对7种降尿酸药品进行评分。结果该标准体系从有效性、安全性、经济性、适宜性、可及性以及创新性6个维度进行量化评分。总分由高到低依次为非布司他(瑞扬)、苯溴马隆(立加利仙)、苯溴马隆(尔同舒)、别嘌醇(奥迈必利)、别嘌醇(久联)、非布司他(菲布力)、丙磺舒。结论本研究以临床价值为导向,构建了一套科学规范的“云南省降尿酸药品临床综合评价与遴选标准体系”,为云南省医疗机构药品配备和采购目录的制定,以及药品合理使用提供科学依据。
OBJECTIVE To establish a clinical comprehensive evaluation and selection criteria system for uric acid-lowering drugs in Yunnan province,providing a reference basis for the rational use of uric acid-lowering drugs in medical institutions in Yunnan province.METHODS According to authoritative guidelines and drug instructions,the Delphi expert consultation method was subjected to seek expert opinions and establish an expert consensus on the evaluation and selection scoring criteria of uric acidlowering drugs in Yunnan Province,and used this scoring criteria to score seven uric acid-lowering drugs.RESULTS The established criteria system adopted a quantitative scoring approach across 6 dimensions,including effectiveness,safety,economy,suitability,accessibility,and innovation.The total scores from high to low were febuxostat(Ruiyang),benzbromarone(Narcaricin),benzbromarone(Ertongshu),allopurinol(Aomaibili),allopurinol(Juilian),febuxostat(Feburic),and probenecid.CONCLUSION Guided by clinical value,this study constructed a scientific and standardized“Clinical Comprehensive Evaluation and Selection Criteria System for Uric Acid-lowering Drugs in Yunnan Province”.It provides a scientific basis for the formulation of drug allocation and procurement catalogs in medical institutions of Yunnan province,as well as the rational use of drugs.
作者
陈新利
雷雨田
杨媛
陈正红
吴晖
CHEN Xinli;LEI Yutian;YANG Yuan;CHEN Zhenghong;WU Hui(Clinical Pharmacy Center,The First Affiliated Hospital of Kunming Medical University,Kunming 650032,China)
出处
《中国现代应用药学》
北大核心
2025年第19期3421-3431,共11页
Chinese Journal of Modern Applied Pharmacy
基金
云南省基础研究专项面上项目(202301AT070152)
云南省中青年学术和技术带头人后备人才项目(202305AC160016)。
关键词
降尿酸药品
临床综合评价
遴选标准
uric acid-lowering drugs
clinical comprehensive evaluation
selection criteria
